04:29 PM EDT, 09/20/2024 (MT Newswires) -- Spyre Therapeutics ( SYRE ) filed a registration statement Friday covering the potential resale of up to about 46.3 million common shares by certain investors.
The company will not receive any of the proceeds from the sale.